Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

157.90 -0.11 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
48 49 Next >
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
Biogen to Acquire Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
--News Direct-- 
Via News Direct
Exposures Product Safety
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
Biogen shares have stagnated in recent years, but the company has a plan to change that. 
Via The Motley Fool
Analyst Ratings for Biogen
Via Benzinga
Biogen (BIIB) Q2 2023 Earnings Call Transcript
BIIB earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Biogen Inc. Tops Q2 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $4.02 per share. 
Via Talk Markets
Better Big Biotech Buy: Vertex vs. Biogen
These companies have a track record of billion-dollar earnings. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today. 
Via The Motley Fool
Why Biogen Stock Got Sick Today
While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light. 
Via The Motley Fool
Biogen Earnings Preview
Via Benzinga
Biogen Unusual Options Activity
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Is Biogen Stock a Buy Now?
The biotech hasn't been the best investment recently. 
Via The Motley Fool
Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories
The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event 
Via Benzinga
WMT Stock Alert: Is Walmart Really Worth $210?
Walmart (WMT) stock is in the news Tuesday as investors react to the latest coverage from Piper Sandler analyst Edward Yruma. 
Via InvestorPlace
MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage
Mobileye (MBLY) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the company's shares. 
Via InvestorPlace
Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts
Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch. 
Via InvestorPlace
Should You Buy the Dip With Biogen Stock Right Now?
It's expected to grow, but things might not work out precisely as planned. 
Via The Motley Fool
P/E Ratio Insights for Biogen
Via Benzinga
Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff
Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con 
Via Benzinga
Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting'
Via Benzinga
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
Analysts expect Biogen to report a a decline in both profits and sales in Q2. 
Via Investor's Business Daily
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc. 
Via Benzinga
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
From Biogen Inc.
Via GlobeNewswire
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price? 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
These 2 Numbers Should Scare Every Biogen Shareholder
There are a couple of pieces of evidence that Biogen's long-term strategy isn't working. 
Via The Motley Fool
7 Stocks That AI Says Will Make You a Millionaire by 2025
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio. 
Via InvestorPlace
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Is the stock a good contrarian buy? 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.